GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
    • Reports
      • GHTM
      • Scientific Advisory Board
      • FCT
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
Home / Archives for Taveira N

Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response

  • Authors: Barroso H, Bártolo I, Borrego P, Calado R, Cavaco-Silva P, Família C, Gomes P, Leitner T, Marcelino JM, Quintas A, Rocha C, Rosado L, Skar H, Taveira N
  • Journal: Retrovirology
  • Link: http://www.retrovirology.com/content/10/1/110

Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+ T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during acute infection and their impact in HIV-2 evolution and disease progression remain largely unknown. Our objective was to characterize the Nab response and the molecular and phenotypic evolution of HIV-2 in association with Nab escape in the first years of infection in two children infected at birth.
Read More

Origin and Epidemiological History of HIV-1 CRF14_BG

  • Authors: Abecasis AB, Barroso H, Bártolo I, Borrego P, Camacho R, Gomes P, McCutchan F, Taveira N
  • Journal: PLoS One
  • Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=26&SID=P2WA5hwy5j35Sqjoq2z&page=1&doc=1

Background: CRF14_BG isolates, originally found in Spain, are characterized by CXCR4 tropism and rapid disease progression. This study aimed to identify the origin of CRF14_BG and reconstruct its epidemiological history based on new isolates from Portugal.
Read More

An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity

  • Authors: Barroso H, Borrego P, Calado R, Marcelino JM, Pereira P, Quintas A, Taveira N
  • Journal: AIDS
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23324659

To produce new fusion inhibitor peptides for HIV-1 and HIV-2 based on ancestral envelope sequences.
Read More

Baseline susceptibility of primary HIV-2 to entry inhibitors.

  • Authors: Antunes F, Barroso H, Bártolo I, Borrego P, Caixas U, Calado R, Cavaco-Silva P, Doroana M, Maltez F, Marcelino JM, Rocha C, Taveira N
  • Journal: Antiviral Therapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Baseline+susceptibility+of+primary+HIV-2+to+entry+inhibitors

BACKGROUND:
The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown.
Read More

Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia.

  • Authors: Baptista AP, Cavaleiro R, Fernandes S, Foxall RB, Gomes P, Marcelino JM, Soares RS, Sousa AE, Taveira N, Tendeiro R, Victorino RM
  • Journal: AIDS
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Memory+B-cell+depletion+is+a+feature+of+HIV-2+infection+even+in+the+absence+of+detectable+viremia

OBJECTIVE:
Memory B-cell loss has long been recognized as an important contributor to HIV immunodeficiency. HIV-2 infection, which is characterized by a slow rate of progression to AIDS and reduced to undetectable viremia, provides a unique model to investigate B-cell disturbances.
Read More

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok